Cancer Biology & Evolution (CBE) is a first-in-kind CCSG Program that emerged from systematic in-house collaborations of mathematicians, evolutionary biologists, and basic and clinical cancer researchers. Although these research teams investigate cancer via traditional means, they include mathematicians and theorists who integrate multi-scalar data through quantitative models founded on evolutionary first principles. Specifically, the CBE integrates the genocentric focus of conventional cancer research into broader Darwinian dynamics where: (i) evolution selects for cellular adaptive phenotypes that emerge in complex ways from both mutations and changes in the expression of normal genes; and (ii) the fitness of each cancer cell is dependent on environmental context and will vary with temporal and spatial changes in the tumor milieu. Mathematicians play critical roles in the CBE Program by deconvoluting the nonlinear dynamics that are manifest in complex open systems such as cancer and by developing and applying mathematical models and computer simulations. The unique scientific ?ecosystem? of the CBE has driven the formation of innovative multidisciplinary teams that are investigating virtually every aspect of cancer biology and therapy through a quantitative evolutionary lens. The overall goals of CBE are to investigate and define the complex dynamics that govern the biology and therapeutic responses of cancer, and to deliver new agents and strategies to prevent and treat refractory or relapsed malignancies. Specifically, CBE Members: (i) generate and apply sophisticated experimental models and methods to define and quantify spatial and temporal dynamics of molecular, cellular, and tissue properties during cancer development, progression, metastasis, and treatment (Aim 1); (ii) develop and test theoretical models, which are based on evolution by natural selection and are parameterized by experimental data, to define cancer dynamics and inform new strategies for control and treatment (Aim 2); and (iii) design new studies and clinical trials that test model predictions, to deliver effective, adaptive therapies into the clinic, and to refine the understanding of cancer biology and therapy (Aim 3). CBE teams have implemented these goals through: (i) combining in vivo and in silico models to understand, prevent and treat metastasis; (ii) targeting never genes, i.e., genes where mutations are never or rarely observed, to produce a durable treatment response; (iii) exploiting tumor dynamics to ?steer? cancers toward a less invasive evolutionary trajectory; (iv) modeling tumor evolutionary strategies that result in therapy resistance; and (v) mathematical models that have been translated into adaptive, personalized clinical trials. The CBE Program has 24 members from nine different academic departments. During the past funding cycle, CBE Members have published 399 cancer- related articles, with 22% representing intra-programmatic publications and 32% being inter-programmatic publications. Total annual grant funding for the CBE Program is robust and is currently at $9.1 million; $8.2 million is peer-reviewed, including $6.3 million from NCI.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
H. Lee Moffitt Cancer Center & Research Institute
United States
Zip Code
Rivera, Y M; Moreno, L; Briant, K J et al. (2018) Developing Sustainable Cancer Education Programs: Training Public Health Students to Deliver Cancer 101 in Puerto Rico. J Cancer Educ 33:128-133
Saltos, Andreas; Khalil, Farah; Smith, Michelle et al. (2018) Clinical associations of mucin 1 in human lung cancer and precancerous lesions. Oncotarget 9:35666-35675
Gjyshi, Anxhela; Dash, Sweta; Cen, Ling et al. (2018) Early transcriptional response of human ovarian and fallopian tube surface epithelial cells to norepinephrine. Sci Rep 8:8291
Maharaj, Kamira; Powers, John J; Achille, Alex et al. (2018) Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia. Blood Adv 2:3012-3024
Schaal, Courtney M; Bora-Singhal, Namrata; Kumar, Durairaj Mohan et al. (2018) Regulation of Sox2 and stemness by nicotine and electronic-cigarettes in non-small cell lung cancer. Mol Cancer 17:149
Zhu, Genyuan; Brayer, Jason; Padron, Eric et al. (2018) OMIP-049: Analysis of Human Myelopoiesis and Myeloid Neoplasms. Cytometry A 93:982-986
Bowman-Curci, Meghan; Quinn, Gwendolyn P; Reinecke, Joyce et al. (2018) Comparing fertility preservation resources and policies between NCCN member and non-member institutions. Support Care Cancer :
Hampras, Shalaka S; Locke, Frederick L; Chavez, Julio C et al. (2018) Prevalence of cutaneous viral infections in incident cutaneous squamous cell carcinoma detected among chronic lymphocytic leukemia and hematopoietic stem cell transplant patients. Leuk Lymphoma 59:911-917
Kim, Youngchul; Pierce, Christine M; Robinson, Lary A (2018) Impact of viral presence in tumor on gene expression in non-small cell lung cancer. BMC Cancer 18:843
Persi, Erez; Duran-Frigola, Miquel; Damaghi, Mehdi et al. (2018) Systems analysis of intracellular pH vulnerabilities for cancer therapy. Nat Commun 9:2997

Showing the most recent 10 out of 1254 publications